Suppr超能文献

[粪便微生物群移植治疗肠道急性移植物抗宿主病]

[Fecal microbiota transplantation for acute graft-versus-host disease of the gut].

作者信息

Kakihana Kazuhiko

机构信息

Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital.

出版信息

Rinsho Ketsueki. 2017;58(5):499-505. doi: 10.11406/rinketsu.58.499.

Abstract

Advances in microbial analysis have provided new insights into the complex interactions between the host and gut microbiota. An imbalance in the gut microbiota (dysbiosis) is associated with various disorders and their pathogenesis. Furthermore, in allogeneic stem cell transplantation, increasing evidence indicates that the gut microbiota is closely associated with acute graft-versus-host disease (GVHD) and transplant outcomes, suggesting that its manipulation could be a new treatment strategy for this acute condition. We conducted a feasibility study of fecal microbiota transplantation (FMT) for acute GVHD of the gut in four human transplant recipients. No severe adverse events that were obviously attributable to FMT were observed. All patients responded to FMT: three patients showed a complete response and one a partial response. Our results indicate that FMT could be a new treatment option for acute GVHD of the gut. However, the use of FMT in treating acute GVHD is in the initial stages of clinical application. FMT has limitations that need to be addressed, such as safety and determination of the optimal donor screening or the treatment protocol. Further evaluation is thus warranted.

摘要

微生物分析的进展为宿主与肠道微生物群之间的复杂相互作用提供了新的见解。肠道微生物群失衡(生态失调)与各种疾病及其发病机制相关。此外,在异基因干细胞移植中,越来越多的证据表明肠道微生物群与急性移植物抗宿主病(GVHD)及移植结果密切相关,这表明对其进行调控可能是治疗这种急性病症的一种新策略。我们对四名人类移植受者进行了粪便微生物群移植(FMT)治疗肠道急性GVHD的可行性研究。未观察到明显归因于FMT的严重不良事件。所有患者对FMT均有反应:三名患者完全缓解,一名部分缓解。我们的结果表明,FMT可能是肠道急性GVHD的一种新的治疗选择。然而,FMT用于治疗急性GVHD尚处于临床应用的初始阶段。FMT存在一些需要解决的局限性,如安全性以及最佳供体筛选或治疗方案的确定。因此有必要进行进一步评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验